# Synthego (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/synthego-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 73.7 |
| Citations | 29,872 |
| City | Menlo Park |
| Country | United States |
| Description | Synthego (United States) is a research organisation in Menlo Park, United States. OpenAlex records 990 works and 29,872 citations for it. 3 researchers list it as their most recent affiliation. |
| Homepage | https://www.synthego.com/ |
| OpenAlex ID | https://openalex.org/I4210102117 |
| Region | California |
| Researchers | 3 |
| ROR ID | https://ror.org/01a3qdh08 |
| Type | company |
| Works | 990 |

## University papers

Showing 12 of 16.

- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer](https://scholariq.org/papers/mutational-landscape-determines-sensitivity-to-pd-1-blockade-in-non-small-cell/)
- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://scholariq.org/papers/tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple/)
- [Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade](https://scholariq.org/papers/clonal-neoantigens-elicit-t-cell-immunoreactivity-and-sensitivity-to-immune/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/overall-survival-and-long-term-safety-of-nivolumab-anti-programmed-death-1/)
- [Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy](https://scholariq.org/papers/patient-hla-class-i-genotype-influences-cancer-response-to-checkpoint-blockade/)
- [Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study](https://scholariq.org/papers/nivolumab-plus-ipilimumab-as-first-line-treatment-for-advanced-non-small-cell/)
- [Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-previously-treated-patients-with-advanced-non/)
- [IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis](https://scholariq.org/papers/il-23-stimulates-epidermal-hyperplasia-via-tnf-and-il-20r2-dependent-mechanisms/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)

## University researchers

- [Naiyer A. Rizvi](https://scholariq.org/researchers/naiyer-a-rizvi/)
- [René de Waal Malefyt](https://scholariq.org/researchers/rene-de-waal-malefyt/)
- [Robert A. Kastelein](https://scholariq.org/researchers/robert-a-kastelein/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.